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The human papillomavirus type 11 (HPV-11) E7 protein can modulate host cell functions and is required for papilloma
formation, but little is known concerning the regulation of its expression. This study was designed to determine whether the
viral upstream regulatory region controlled expression from the E7 promoter and whether cis sequences differentially
regulated E6 and E7 expression in laryngeal mucosal keratinocytes, the natural target cells for this virus. Reporter constructs
were designed to study expression of the luciferase gene from the HPV-11 E7 promoter in its natural position downstream
of a functional E6 promoter. E7 expression, like E6 expression, required upstream regulatory sequences. However, E7
expression was less sensitive to repression by viral E2 protein and to mutation of the SpI binding site adjacent to the E2
binding site. Moreover, there was differential sensitivity of the two promoters to mutation of the E6 TATA box, with E7
expression more affected than E6 expression. These findings show that, in the normal host cells for this virus, the E6 and
E7 promoters can be independently regulated by the cis regulatory region adjacent to the E6 promoter. © 1998 Academic Press
INTRODUCTION
Human papillomavirus type 11 (HPV-11) and the
closely related HPV-6 are the etiologic agents of benign
human tumors including laryngeal (Gissmann et al.,
1982b; Mounts et al., 1982) and conjunctival (McDonnell
et al., 1987) papillomas and anogenital condylomas (de-
Villiers et al., 1981; Gissmann et al., 1982a). These vi-
ruses have been termed low-risk HPVs to distinguish
them from the high-risk viruses (such as HPV-16), which
are more often associated with malignancies. The viral
genome encodes proteins that can alter the differentia-
tion (Steinberg et al., 1990) and growth characteristics
(Chen and Mounts, 1990; Halbert et al., 1992; Schlegel et
al., 1988; Cheng et al., 1995) of the infected host cell, as
well as proteins that regulate viral functions including
viral DNA replication (DelVecchio et al., 1992) and tran-
scription (Dollard et al., 1993). The viral E7 protein is of
particular interest, because it affects both the host cell
and the viral life cycle.
The E7 proteins of HPV-6 and HPV-11 bind Rb (Munger
et al., 1989), the tumor suppressor protein encoded by
the retinoblastoma susceptibility gene. Rb normally pre-
vents cells from inappropriately entering the S phase of
the cell cycle by binding the transcription factor E2F and
preventing E2F-mediated activation of genes required for
S-phase entry or DNA synthesis. E7 can also bind other
cell cycle regulators, including p107 and cyclin-depen-
dent kinase 2—cyclin A (Ciccolini et al., 1994). Although
E7 proteins of HPV-6 and HPV-11 bind these proteins
with a lower affinity than do the E7 proteins of the
high-risk HPVs, E7 proteins from both groups are equally
capable of transactivating an E2F-responsive promoter
(Munger et al., 1991). In addition, E7 protein can reacti-
vate the expression of cellular DNA replication proteins
in differentiated keratinocytes, thus allowing viral DNA
replication in nondividing cells (Cheng et al., 1995). Con-
sistent with this function, the E7 gene was found to be
essential for papilloma formation in the cottontail rabbit
papillomavirus animal model for papillomavirus-induced
lesions (Brandsma et al., 1991).
Viral E6 and E7 transcripts of the high-risk HPVs initi-
ate from a single promoter. In contrast, HPV-11 E6 and E7
transcripts initiate at two different promoters (Smotkin et
al., 1989) whose putative TATA elements are at nt 66–71
and nt 229–234, respectively (Fig. 1A). Transcription from
the upstream E6 promoter proceeds through and past
the E7 promoter region within the E6 open reading frame
(ORF), continuing to the common early region termination
site at approximately nt 4400. Thus transcripts from the
E7 promoter would express E7 protein, while transcripts
from the E6 promoter could potentially code for both E6
and E7 proteins in two different reading frames. How-
ever, Halbert et al., (1991) and Stacey et al., (1995) re-
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ported that the bicistronic HPV-6 and HPV-11 E6/E7 mR-
NAs cannot express E7 protein.
We previously showed by RNase protection analysis
that both the E6 and E7 promoters are active in laryngeal
papillomas and in cultured cells derived from them and
that the two promoters could be differentially regulated
by changing culture conditions (DiLorenzo and Stein-
berg, 1995). Extensive studies have shown that the E6
promoter is regulated by sequences within the viral up-
stream regulatory region (URR) that bind viral and host
proteins (Chin et al., 1988, 1989; Hirochika et al., 1988;
Auborn et al., 1989; Dollard et al., 1993; Dong et al., 1994;
O’Connor et al., 1995). However, much less is known
concerning the importance of the URR in regulating
HPV-11 E7 expression or whether cis elements within
this region contribute to differential regulation of the two
promoters. Rapp et al., (1997) very recently reported that
viral E2 protein can differentially regulate the HPV-6a E6
FIG. 1. Effects of deletions of the URR on expression of luciferase from HPV-11 E6 and E7 promoter constructs. (A) A partial map of HPV-11 DNA.
The horizontal line represents HPV-11 sequences from nt 7178–7931/0–826. Relevant nucleotide numbers for this study are as follows: E2 binding
sites, 7890–7901, 35–46, 50–61; GRE, 7674–7688. SpI binding site, 28–33; E6 TATA box, nt 66–71; E6 RNA start site (first arrow), nt 99; E7 TATA box,
nt 229–234; E7 RNA start site (second arrow), nt 264; E6 stop codon, nt 552–554; E7 stop codon, nt 824–826. Boxes represent E6 and E7 coding
sequences. Note that the E6 stop codon is downstream of the E7 start codon. (B) Effect of 59 deletions of the URR on relative expression from the
E6 promoter construct. Shaded boxes are the HPV-11 sequences; open boxes are the luciferase vector. Constructs were transfected into laryngeal
keratinocytes, and the relative luciferase levels normalized to the full-length URR. Values are expressed as means of three experiments with different
primary cell strains, 6 SE. (C) Effect of 59 deletions of the URR on relative expression from the E7 promoter construct. Shaded boxes are the HPV-11
sequences; open boxes are the luciferase vector. Constructs were transfected into laryngeal keratinocytes, and the relative luciferase levels
normalized to the full-length URR. Values are expressed as means of three experiments with different primary cell strains, 6 SE.
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and E7 promoters through E2-binding sites within the
URR, but that differential regulation varied among immor-
talized cell lines.
The goal of this study was to determine whether the
URR regulates the HPV-11 E7 promoter in primary laryn-
geal keratinocytes, the normal host cells, and whether
the two promoters can be differentially regulated. The
approach was designed to use reporter constructs that
mimic the viral structure, with the E7 promoter in its
normal position downstream of a functional E6 promoter.
We have shown that URR sequences are required for E7
expression in normal host cells for this virus. We have
also shown that E6 and E7 expression can be differen-
tially regulated by URR elements near the E6 promoter.
RESULTS
The parental p(7178-530)luc construct contained both
E6 and E7 promoters. To confirm that it expressed lucif-
erase from the E7 promoter, rather than the E6 promoter,
we created a mutation in the E7 TATA box to generate
p(7178-530-E7 TATA)luc. Both the parental and E7 TATA
mutant constructs were microinjected into normal laryn-
geal keratinocytes, with 300 cells injected per construct
per experiment. Two separate experiments with different
cell strains gave comparable results, averaging a 97%
reduction in luciferase expression when the E7 TATA box
was mutated. From this data we concluded that the
expression of luciferase from p(7178-530)luc and its de-
rivative constructs reflected transcription from the E7
promoter.
To determine whether the E6 and E7 constructs were
expressed differentially in primary laryngeal keratinocytes
or an established head and neck carcinoma line, and
whether E7 expression required the URR, p(7178-100)luc,
p(33-100)luc, p(7178-530)luc, and p(33-530)luc were micro-
injected into cells of each type. Both constructs containing
the full-length URR expressed luciferase in laryngeal kera-
tinocytes and in the carcinoma line UM-SCC-1, with varia-
tions in level of expression as a function of culture condi-
tions (data not shown). Neither construct lacking the URR
expressed detectable luciferase. The expression was ap-
proximately 20-fold less in UM-SCC-1 cells than in mucosal
keratinocytes. Therefore, normal target cells for HPV-11
were most appropriate for the studies, reaffirming our ear-
lier findings (Steinberg et al., 1989) that all epithelial cells
are not equivalent and highlighting the importance of utiliz-
ing the natural host cells in viral expression studies when-
ever possible. These results also clearly indicated a re-
quirement for URR sequences for expression of the E7
construct.
We then asked whether control of the two promoters
could be dissected and which region of the viral URR
was required for luciferase expression from the E7 con-
struct. To do this, we made parallel 59 progressive dele-
tions of the URR for both E6 and E7 expression con-
structs (Figs. 1B and 1C). Transfection was used for
these and all subsequent experiments. Clearly, se-
quences at the 59 end of the URR could be eliminated
with no effect on expression, while sequences between
nt 7220 and 7658 were required for full expression but
were not essential. Deletion of sequences between nt
7658 and 7899 abolished essentially all detectable ex-
pression. In these studies, the URR region required for
E7 expression appeared similar to that for E6 expression.
The constructs containing URR sequences from nt
7658 to 33 showed the greatest variability in these as-
says. The large standard deviation with these constructs
was the result of intrinsic differences in expression from
one primary cell strain to another, not variability within
the replicate samples of a single experiment. The data
suggest possible variation in the use of cis sequences in
this region of the URR among primary cells derived from
different patients, with much less difference for se-
quences in other parts of the URR. In fact, requirement
for these sequences was more variable for E7 expres-
sion than for E6 expression, consistent with the findings
of Rapp et al., (1997) that different immortalized cell lines
showed variation in expression from the E7 promoter. We
have described differences between primary laryngeal
keratinocyte cultures in other studies (DiLorenzo and
Steinberg, 1990).
The mucosal HPVs contain a consensus sequence for
a glucocorticoid response element (GRE). This element
binds the rat glucocorticoid receptor and acts as a dex-
amethasone-responsive enhancer when cloned up-
stream of the herpes simplex virus thymidine kinase
promoter or the HPV-16 E6/E7 promoter (Gloss et al.,
1987; Chan et al., 1989). When the SV40 early coding
region is put under the control of HPV-11 regulatory
sequences including the GRE, the resulting construct
transforms baby rat kidney cells in cooperation with
activated Ha-ras, with dexamethasone greatly increasing
the number of transformed colonies (Pater et al., 1988).
However, this stimulation could reflect both direct and
indirect effects on transcription. In HPV-11, the GRE is
located at nt 7674–7688 (Chan et al., 1989), which is
within the region we found necessary for luciferase ex-
pression. Since our transfections were done in KGM
containing hydrocortisone, we asked if glucocorticoids
regulated E7 expression and whether loss of the GRE
contributed to the loss in enhancer activity for the E7 and
E6 deletion constructs.
To address these questions, we chose to measure the
effect of glucocorticoids on the expression of the two
full-length URR constructs, rather than generating GRE
mutants. In this way we could measure both direct ef-
fects of activated glucocorticoid receptor binding to the
GRE and indirect effects with glucocorticoids modulating
other transcription factors that would then affect E7 ex-
pression. A preliminary experiment with the glucocorti-
coid-dependent construct pAHluc suggested that the
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glucocorticoid receptor in the laryngeal keratinocytes
might be limiting. Therefore, the experiments were done
with and without cotransfection of the receptor expres-
sion plasmid. The results of three separate experiments
are shown in Table 1. In the absence of exogenous
receptor, none of the constructs showed any stimulation
with dexamethasone. When the receptor plasmid was
coexpressed, the positive control construct pAHluc
showed marked increases in expression with addition of
dexamethasone. In contrast, there was only a slight
increase for the two HPV-11 constructs. These results
suggest that deletion of the GRE did not contribute to the
loss of expression seen in the URR deletion constructs.
They also suggested that neither promoter was directly
or indirectly stimulated by the presence of glucocorti-
coids in the context of a full-length HPV-11 URR function-
ing in the normal target cells for this virus. This is in
agreement with the recent findings of Khan et al., (1997),
who have found that glucocorticoids enhance HPV-16-
induced transformation of foreskin keratinocytes and en-
hance proliferation of early passage HPV-16-immortal-
ized cells, but that this is not directly mediated through
increased expression of E6/E7 mRNA. We would con-
clude from this data that glucocorticoids mediate their
effects through changes in other cellular functions.
The region from nt 7658 to 66 contains a large number
of other binding sites for both cellular and viral transcrip-
tion factors (O’Connor et al., 1995). The viral E2 protein
binds to its cognate binding site at nt 7890–7901, 35–46,
and 50–61. Binding at nt 35–46 can repress E6 transcrip-
tion by interfering with the binding of SpI at nt 28–33
(Dong et al., 1994), with the repression dependent on the
amount of E2 protein present. In constructs containing
the HPV-11 URR upstream of a heterologous promoter,
E2 can enhance transcription (Hirochika et al., 1988). We
therefore asked whether coexpression of E2 from a het-
erologous promoter would alter luciferase expression
from the E7 construct in the same way as had been
reported for E6 (Fig. 2A). The lower concentration of
pCMV-E211 was used in one experiment and showed the
TABLE 1
Effects of Dexamethasone on E6 and E7 Expression
Expression
construct
Stimulation by dexamethasone
Without exogenous
receptor
With exogenous
receptor
p(7178-100)luc 1.28 6 0.47 1.81 6 0.53
p(7178-530)luc 0.90 6 0.17 2.10 6 0.40
pAHluc 1.23 6 0.39 174.66 6 38.55
Note. Laryngeal keratinocytes were cultured for 4 days in the ab-
sence of hydrocortisone and transfected with the luciferase reporter
construct with or without the plasmid pSV2wRec, which expresses the
murine glucocorticoid receptor. Cells were then cultured for an addi-
tional 2 days with or without dexamethasone and assayed for lucif-
erase activity. Results are the means of three experiments, normalized
to the results without dexamethasone, and expressed as fold in-
crease 6 standard error. pAHluc is a positive control, with the lucif-
erase gene under the control of the glucocorticoid-responsive mouse
mammary tumor virus promoter.
FIG. 2. Regulation of E6 and E7 expression by URR sequences. (A) The effect of HPV-11 E2 protein on E6 and E7 expression. Laryngeal
keratinocytes were transfected with p(7178-100)luc or p(7178-530)luc, plus the indicated amounts of the pCMV-E211 expression construct. Total CMV
promoter levels were kept constant by addition of appropriate amounts of pCMV4. Values are expressed as percent of control without E2 protein. Error
bars on the 0.5-mg data indicate standard error of three experiments. (B) Effect of SpI mutation on E6 and E7 expression. Cells were transfected with
the parental constructs p(7178-100)luc or p(7178-530)luc (WT) or mutant constructs p(7178-100-SpI)luc or p(7178-530-SpI)luc (Mutant). Data are
expressed as percentages of wild-type (WT) control constructs with an intact SpI site. Bars indicate standard error of three experiments.
133REGULATION OF THE HPV-11 E7 PROMOTER
modest stimulation of E6 expression that had been pre-
viously reported (Hirochika et al., 1988). There was no
significant effect on E7 expression. The response of the
E6 construct to a higher concentration of pCMV-E211 was
also as expected: marked reduction in luciferase expres-
sion. In contrast, the E7 construct showed only a modest
reduction at the higher concentration. Increasing the
pCMV-E211 construct to 1 mg in a separate experiment
with the p(7178-530)luc reporter construct did not reduce
the level of expression further (data not shown).
The result with the viral E2 expression construct sug-
gested that the SpI site might not be as essential for E7
expression as for E6 expression. To confirm this directly, we
mutated the SpI site and then compared the mutant con-
structs to the parental constructs (Fig. 2B). Supporting this
hypothesis, loss of the SpI site caused greater than 70%
reduction in E6 expression, but only reduced expression
from the E7 construct by 25%. It would therefore appear that
the SpI site is only minimally required for E7 expression
when analyzed within the context of the full-length URR and
that the E6 and E7 promoters can respond differently to
regulation of the same cis URR sequences.
Transcription from an upstream promoter that extends
through a downstream promoter can interfere with the
initiation of transcripts at the distal promoter. This phe-
nomenon is referred to as promoter occlusion or tran-
scriptional interference (Adhya and Gottesman, 1982;
Corbin and Maniatis, 1989). Sequences that directly
modulate the E6 promoter could indirectly affect E7 if
promoter occlusion plays a role in limiting E7 expression.
Mutation of the SpI site could conceivably have had two
opposite effects on E7: release of promoter occlusion
from E6 which would result in increased expression of
E7 and a direct suppression if SpI were a transcription
factor that stimulated expression from E7. The two effects
would counter each other when expression from the
p(7178-530-SpI) mutant construct was measured.
Continuing our studies to dissect the control of the two
promoters, we mutated the E6 TATA sequence to ask
whether promoter occlusion affects E7 expression. Our
expectation was a reduction in E6 expression with either
increased E7 expression or no effect. However, the effect
of mutating the E6 TATA sequence was a greater sup-
pression of E7 than of E6 (Table 2). Minimal or no reduc-
tion in transcription following TATA mutation has been
described previously in other systems (Majumder and
DePamphilis, 1994). Of more interest is the marked re-
duction in transcription from E7. This result would
strongly suggest that the sequences at nt 66–71 are
somehow essential for E7 expression and again shows
that the two promoters are not necessarily coordinately
regulated. This result further confirms our decision to
study the E7 promoter in its normal association with a
functional E6 promoter.
We used a recently described RT–PCR amplification
method (SPACE; Bostik et al., 1997) to individually detect
E6 and E7 transcripts (Fig. 3). Figure 3A illustrates the
overall SPACE method. With RNA extracted from a laryn-
geal papilloma (Fig. 3B), E7 transcripts were more readily
detected than E6 transcripts, while E6 transcripts were
more abundant in the transfected cells (Fig. 3C). These
results agreed with RNase protection analysis of the
relative abundance of the endogenous viral transcripts in
papillomas and cultured papilloma cells. E7 mRNA was
more abundant in tissue, and E6 mRNA more abundant
in cultured cells (DiLorenzo and Steinberg, 1995). There-
fore, RNA from the parental construct p(7178-530)luc was
expressed in a similar manner to RNA from the intact
viral genome in cultured papilloma cells. Moreover, this
result confirmed that the method was able to detect
differences in relative abundance of the two transcripts.
The SPACE approach confirmed that patterns of tran-
script abundance from p(7178-530)luc, p(7178-530-E6
TATA)luc, p(7178-530-E7 TATA)luc, and p(7178-530-SpI)luc
were consistent with the luciferase results. Mutation of
the E6 TATA box reduced E6 RNA only marginally, but
caused a marked reduction in E7 RNA, parallel to the
luciferase data in Table 2. Conversely, mutation of the E7
TATA box markedly reduced E7 RNA but not E6 RNA.
Finally, mutation of the SpI binding site reduced E6 RNA
to below detectable levels, but had no marked effect on
detection of E7 RNA, in agreement with the luciferase
data in Fig. 2. The results further substantiated the con-
clusion that luciferase expression from p(7178-530)luc
was derived predominantly if not exclusively from the E7
promoter and that the luciferase levels reflected the RNA
levels.
DISCUSSION
Papillomavirus expression and replication are coordi-
nately regulated as the host epithelial cell completes its
differentiation. In the basal and suprabasal layers of
stratified squamous tissue, comparable to monolayer
cultures of keratinocytes, modest levels of E6 and E7
mRNA are expressed. E6 is predominantly in the basal
TABLE 2
Effect of Mutation of the E6 TATA Box on E7 Expression
Parental expression
construct
Relative expression
Wild type E6 TATA mutant
p(7178-100)luc 1.00 0.44 6 0.08
p(7178-530)luc 1.00 0.13 6 0.03
Note. Early passage laryngeal keratinocytes were transfected with
either the wild-type constructs p(7178-100)luc or p(7178-530)luc or con-
structs p(7178-100-E6 TATA)luc and p(7178-530-E6 TATA)luc, mutated at
the E6 TATA box at nt 66–71. Luciferase levels were measured 48 h later
and normalized to b-gal expression from a cotransfected pCMV-b-gal
construct. Results are expressed as mean reduction relative to the
wild-type construct, 6 standard error of three experiments.
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layer and E7 in the suprabasal layer (Stoler et al., 1989;
Iftner et al., 1992). As the cells differentiate, Stoler et al.,
(1989) reported that higher levels of E7 are expressed.
This presumably results in induction or maintenance of
the host DNA replication machinery so that the viral DNA
can be replicated (Cheng et al., 1995). Levels of E6 are
not increased, and there is evidence that E6 transcription
is reduced or eliminated (Iftner et al., 1992). Therefore,
there must be one or more mechanisms to indepen-
dently regulate the two promoters. These could involve
changes in cellular transcription factors, possibly inter-
acting with viral regulatory proteins. This type of shift is
also seen in other viruses. For example, Woisetschlaeger
et al. (1990) described a promoter switch in Epstein–Barr
virus-infected lymphocytes associated with the transition
from initial establishment of latent infection in resting B
cells to a fully established latent infection in proliferating
lymphoblastoid cells.
We have shown in this study that, in the normal target
cells for HPV-11, the E7 promoter construct is regulated
by the viral URR and that the E7 promoter can respond
differently from the E6 promoter to both viral E2 protein
and to the cellular transcription factor SpI. In more dif-
ferentiated epithelium, transcription from a third pro-
moter is markedly increased (Hummel et al., 1992;
DiLorenzo and Steinberg, 1995). This generates high
levels of transcripts that include the E2 transcripts. It is
possible to envision a scenario that would include in-
creased levels of E2 preferentially suppressing the E6
promoter at the SpI site and changes in expression of
one or more cellular transcription factors that would
specifically increase E7 transcription. Perhaps the vari-
ation seen in expression of the p(7178-100)luc and
p(7658-530)luc constructs in the different cell strains was
due in part to variation in commitment to differentiation,
with concomitant differences in levels of critical tran-
scription factors.
Effects of mutating the E6 TATA box sequence reflect
the complex regulation of viral and eukaryotic promoters.
Although it is generally accepted that mutation of the
TATA box results in marked down-regulation of expres-
sion, Majumder and DePamphilis (1994) described a
differentially regulated switch from TATA-independent to
TATA-dependent expression of the basal herpes simplex
thymidine kinase promoter in early mouse embryos, with
two-fold higher expression from the TATA box mutant.
FIG. 3. Analysis of RNA from the HPV-11 E6 and E7 luciferase promoters. Total cellular RNAs from laryngeal papilloma tissue and from cells
transfected with wild-type (WT) and mutant E7 promoter constructs were analyzed by primer extension and RT–PCR, using the SPACE technique
(Bostik et al., 1997), which permits analysis of overlapping RNAs with defined separate 59 ends. (A) Cartoon showing the SPACE technique. Following
cDNA synthesis using an HPV-11-specific primer, the 39 ends of cDNAs corresponding to the E6 and E7 transcripts were extended on templates
containing sequences from nt 88 to 109 for E6 transcripts and nt 257 to 291 for E6 transcripts. Although E6 transcripts would contain the sequences
from 257 to 291, they are internally located within the cDNA and therefore E6 cDNAs cannot be extended on E7 extension templates. Thus each
extension template is specific for RNA species whose 59 end sequences are included within the template. After extension, the cDNAs are amplified
using a primer homologous to the common non-HPV sequence indicated by the open dashed rectangle, eliminating any difference in PCR
amplification efficiency due to differences in primer sequences. (B) SPACE analysis of RNA extracted from a laryngeal papilloma. E6: Amplified
fragment using the E6 extension template. E7: Amplified fragment using the E7 extension template. Size of products is shown in base pairs (BP). (C)
SPACE analysis of RNA extracted from primary normal laryngeal cells transfected with E7 luciferase constructs. WT: p(7178-530)luc. SPI: p(7178-530
SpI)luc. E7 TATA: p(7178-530 E7 TATA)luc. E6 TATA: p(7178-530 E6 TATA)luc. First four lanes: E6 extension template, generating a 449-bp fragment.
Negative control: PCR amplification of RNA from cells transfected with p(7178-530)luc without synthesis of cDNA or template extension. Last four
lanes: E7 extension template, generating a 280-bp fragment.
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Cultured mouse embryo fibroblasts and 3T3 cells also
exhibited similar thymidine kinase TATA-independent ex-
pression, and we have now shown TATA-independent E6
expression in cultured primary laryngeal keratinocytes.
An additional potential function of the TATA box and its
associated proteins, beyond initiation of transcription,
has also been described (Seipel et al., 1994). Both RNA
polymerase II and TATA binding protein contain domains
that function as transcriptional activators when fused to
a GAL4 DNA-binding domain and transfected into HeLa
cells along with GAL4 reporter constructs. Thus the
HPV-11 E6 TATA box may bind cellular proteins that
cooperate with enhancer-binding proteins targeted to
the URR to activate the E7 TATA box.
We had considered the possibility that some of the
luciferase expressed by the E7 promoter constructs is
actually from a transcript initiating at E6. Our E7 promoter
constructs terminate translation of the E6 open reading
frame within the luciferase gene, similar to the normal
viral termination within the E7 gene. Peabody and Berg
(1986) had reported that ribosomes can reinitiate on a
bicistronic mRNA coding for mouse dihydrofolate reduc-
tase followed by bacterial xanthine guanine phosphori-
bosyl transferase, with an overlap of up to 50 nt. How-
ever, Halbert et al. (1991) and Stacey et al. (1995) have
both reported that the bicistronic E6/E7 mRNAs cannot
express E7 protein.
Our data are not consistent with significant expression
from an E6 mRNA in p(7178–530)luc. First, mutation of the
E7 TATA box reduced luciferase expression by almost 2
orders of magnitude, strongly suggesting that the lucif-
erase was derived from an E7 transcript. Second, the
luciferase data is consistent with the relative amplifica-
tion of E6 and E7 mRNAs shown in Fig. 3. While RT–PCR
is not quantitative, relative amplification in this study
should reflect relative abundance of the initial viral RNAs.
Amplifications of both the E6 and E7 cDNAs used the
same primer pair and the relative abundance of the two
transcripts from the transfected cells and tissue were
consistent with our earlier RNase analysis of papillomas
and cultured papilloma cells (DiLorenzo and Steinberg,
1995). Finally, if a constant percentage of luciferase were
expressed from the E6 transcript in our E7 construct,
changes in E7 expression would be proportional to E6
expression. We have seen significant reductions in E6
with a lesser reduction in E7 (Fig. 2) and a drop in E7 with
only a modest reduction in E6 (Table 2).
Rapp et al., (1997) recently reported that similar lucif-
erase constructs containing HPV-6a sequences showed
independent regulation of the E6 and E7 promoters by
viral E2 protein in some of the established cell lines they
studied. They found that the differential use of the two
promoters was cell line dependent. Moreover, all of their
analysis comparing the relative use of the promoters and
the effects of E2 protein, E2 binding site mutants, and
TATA box mutants was done in established cell lines,
precluding direct comparison with our results in primary
normal cells. Differences between their studies and ours
on the effects of the E6 TATA mutation, for example, could
reflect differences in abundance or identity of enhancer
binding proteins with the cells.
We propose that in the normal target cells for HPV-11 the
E7 promoter is independently regulated by binding of cel-
lular factors to cis sequences in the URR, including the
TATA sequence at nt 66–71. This independent regulation
would permit the intracellular environment to regulate the
relative and absolute levels of E6 and E7 protein as the
cells stratify and differentiate within a papilloma.
MATERIALS AND METHODS
Preparation of HPV reporter constructs
A map of a portion of HPV-11, containing the URR and the
E6 and E7 open reading frames, is shown in Fig. 1A.
Sequences from nt 7178–100, 33–100, 7178–530, or 33–530
were amplified by PCR using the proofreading DNA poly-
merase from Pyrococcus furiosus (Stratagene) and cloned
into the SmaI site of the pGL3-Basic vector (Promega) to
generate p(7178-100)luc, p(33-100)luc, p(7178-530)luc, and
p(33-530)luc, respectively. p(7178-100)luc contains the URR
and the E6 promoter sequences 59 to the E6 AUG. Lucif-
erase expression from this construct will be referred to as
‘‘E6 expression.’’ p(7178-530)luc contains the URR and all
sequences between the URR and the E7 AUG, maintaining
the normal relationship between the E6 and E7 promoters.
Luciferase expression from this construct will be referred to
as ‘‘E7 expression.’’ p(7220-100)luc and p(7220-530)luc were
generated from the parental p(7178-100 or -530)luc con-
structs by digestion with SmaI and PvuII, p(7899-100)luc
and p(7899-530)luc by digestion with SmaI and BstEII.
p(7658-100)luc was generated by digesting p(7178-100)luc
with MluI (located in the vector multiple cloning site) and
NdeI. p(7658-530)luc was constructed by replacing the
KpnI–BstEII fragment of p(7178-530)luc with the shorter
KpnI–BstEII fragment derived from p(7658-100)luc.
Four constructs with site-specific mutations were gener-
ated from the parental p(7178-100 or -530)luc constructs by
site-specific PCR mutagenesis (Higuchi, 1990). p(7178-100-
SpI)luc and p(7178-530-SpI)luc contained mutations of the
SpI binding site at nt 28–33, converting the sequence from
AGGAGG to CTTAAG. The E6 TATA box at nt 66–71 was
converted from TATAAA to CTGCAG, generating p(7178-
100-E6 TATA)luc and p(7178-530-E6 TATA)luc. Similarly, the
E7 TATA box at nt 244–248 was converted from TATAA to
CTGCAG, generating p(7178-530-E7 TATA)luc. All con-
structs were confirmed by sequencing.
In all of the constructs, the luciferase gene was down-
stream of the E6 or the E7 promoters. It should be noted
that in HPV-11, the E6 stop codon occurs 22 nt down-
stream of the E7 start codon. Similarly, in the E7 con-
structs, translation from E6 mRNA terminates 19 nt be-
yond the luciferase start codon.
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Other constructs
Additional constructs were also used in the study.
pCMV-b-gal expresses b-galactosidase from the cyto-
megalovirus (CMV) immediate-early promoter and en-
hancer (MacGregor and Caskey, 1989). pCMV-E211 is an
expression construct for HPV-11 E2 protein (DelVecchio
et al., 1992), with E2 sequences cloned into pCMV4
(Andersson et al., 1989) under the control of the CMV
enhancer and promoter. pAHluc is a glucocorticoid-in-
ducible luciferase plasmid containing the mouse mam-
mary tumor virus promoter (Nordeen, 1988). pSV2wRec is
an expression construct for the murine glucocorticoid
receptor (Danielsen et al., 1986).
Microinjection of constructs
Luciferase reporter constructs were microinjected in-
dividually into mucosal keratinocytes derived from nor-
mal laryngeal epithelium (Steinberg et al., 1982) grown
on coverslips in Ham’s F12 supplemented with 10 mg/ml
hydrocortisone and 10% Fetal Clone II serum (Hyclone),
into HPV-negative UM-SCC-1 oral carcinoma cells
(Krause et al., 1981) cultured in MEM containing 10%
Fetal Clone II serum, or into either primary cells or
UM-SCC-1 cultured in serum-free keratinocyte basal me-
dium (KBM, Clonetics) supplemented with 1 ng/ml epi-
dermal growth factor, 5 mg/ml insulin, 2 mg/ml transferrin,
11 mg/ml bovine pituitary extract (Clonetics), 0.5 mg/ml
hydrocortisone, 1029 M all-trans retinoic acid, 100 U/ml
penicillin, 100 mg/ml streptomycin, and either 0.15 or 1
mM CaCl2 (KGM). One hundred to 300 cells per coverslip
were injected with 20 copies/cell of each construct an-
alyzed. Luciferase was assayed 48 h after microinjection.
Transfection of constructs
Early passage laryngeal keratinocytes from normal
tissue or laryngeal papillomas were cultured in 2-cm2
wells in serum-free KGM until approximately 80% conflu-
ent. Cells were transfected using a modified Polybrene
procedure (Dollard et al., 1993) with 2.5 mg luciferase
construct and 0.5 mg pCMV-b-gal (except where indi-
cated) and 6 mg Polybrene in a final volume of 150
ml/well antibiotic-free KGM. After incubation at 37°C for
5 h, the DNA mixture was removed and cells were
incubated in 15% glycerol in KBM at room temperature
for 2 min. Cells were rinsed with KBM, fed with KGM, and
refed the next day. All experiments were done in dupli-
cate wells and each experiment was repeated at least
twice. Early passage cells derived from different patients
were used in different experiments. Normal and papil-
loma cells gave comparable transfection efficiencies.
For RNA analysis, cells were cultured in 35-mm
dishes, transfected with 2 mg of each construct DNA
using lipofectin (Gibco BRL) as described by the man-
ufacturer, incubated for 24 h, washed, and refed with
FAD medium containing 10% fetal calf serum (Rhein-
wald and Green, 1975). RNA was extracted 48 h later
for analysis.
Luciferase assays
Two days after transfection, aliquots from each well
were used to measure luciferase and b-galactosidase
expression using Promega’s Luciferase Assay System
and b-galactosidase Enzyme Assay System, respec-
tively. Absolute amounts of luciferase were determined
by comparison to a standard curve prepared using puri-
fied luciferase (Boehringer Mannheim), ranging from 0 to
200 fg. The luciferase assay is linear over at least 8 logs,
and we could accurately read as little as 4 fg enzyme.
Absolute luciferase levels in the different experiments
ranged from 4500 to 85,500 fg/well for p(7178-100)luc and
228 to 13,932 fg/well for p(7178-530)luc. The variation
reflects differences from one primary cell preparation to
another, with results within an experiment internally con-
sistent. Luciferase levels were then normalized to b-ga-
lactosidase levels, to correct for any differences in trans-
fection efficiency, and expressed as the percentage of
control 6 standard error (SE).
Glucocorticoid response
Cells were cultured in KGM lacking hydrocortisone
and bovine pituitary extract for 4 days, transfected with
1.25 mg p(7178-100)luc or p(7178-530)luc, 0.5 mg pCMVb-
gal, and either 1.25 mg pGL3-Basic or 1.25 mg pSV2wRec,
and then fed KGM with or without 1026 M dexametha-
sone for 2 days before extraction for luciferase activity.
RNA analysis
Cells were transfected with p(7178-530)luc, p(7178-
530-SpI)luc, p(7178-530-E6 TATA)luc, and p(7178-530-E7
TATA)luc as described above. Total RNA was isolated
with RNA STAT-60 (Tel-Test) and quantified by optical
density. Of each RNA preparation, 1.5 mg was incubated
with 10 U DNase (Boehringer Mannheim) for 1 h at 37°C
to remove any residual DNA contamination, the DNase
inactivated by heating to 65°C for 20 min and cDNA
prepared from 600 ng of the treated RNA sample using
AMV reverse transcriptase and an HPV-specific primer
from nt 516–530 as previously described (Maran et al.,
1995). E6 and E7 transcripts were analyzed from 10% of
the cDNA preparation by the SPACE technique (Bostik et
al., 1997), which permits specific amplification of cDNA
ends from overlapping transcripts with discrete 59 ends.
cDNAs were extended for four cycles with Taq polymer-
ase by denaturing at 94°C for 30 s annealing at 55°C for
30 s and extending at 71°C for 1 min. The sequence of
the template for extension of the E6 cDNA was 59ggc-
gtacaacccctcGCAGACGAGGCATTATTGAAAGattt39, with
HPV-11 sequences (nt 88 to 109) shown in caps. The
extension template for E7 cDNA was 59ggcgtacaacc-
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cctcGGTTGTGTGGCGAGACAACTTTCCCTTTGCAGCGT-
acac39, with the HPV-11 sequences from nt 257–291
shown in caps. The two HPV-11 E7 transcripts initiate at
nt 264 and 270 (Smotkin et al., 1989). PCR amplification of
the extended cDNAs was done as previously described
(Maran et al., 1995), using 35 cycles of 94°C for 30 s,
50°C for 30 s, and 72°C for 1 min. The amplification
primers consisted of the common sequence at the 59
ends of the two extension templates (ggcgtacaacccctcG)
paired with a primer from HPV sequence nt 494–522.
Thirty percent of each PCR product was analyzed by
Southern blot, using a digoxigenin-labeled HPV-11 probe
from nt 493–522. Products were visualized by the Genius
chemiluminescence method using manufacturer’s direc-
tions (Boehringer Mannheim).
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